# Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)

> **NCT05946148** · — · COMPLETED · sponsor: **National and Kapodistrian University of Athens** · enrollment: 78 (actual)

## Conditions studied

- Non-Alcoholic Fatty Liver Disease
- Liver Steatosis

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Dulaglutide
- **DRUG:** Control Rx

## Key facts

- **NCT ID:** NCT05946148
- **Lead sponsor:** National and Kapodistrian University of Athens
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-01
- **Primary completion:** 2021-05-31
- **Final completion:** 2021-05-31
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2023-07-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05946148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05946148, "Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05946148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*